Based on FDA feedback, Bellerophon Therapeutics (BLPH +12%) has set the key aspects
of its planned Phase 3 clinical trial evaluating INOpulse for the
treatment of pulmonary hypertension associated with pulmonary fibrosis.
The primary endpoint will include the use of moderate-to-vigorous physical activity. The trial should launch shortly.
Results from a Phase 2 study, announced about a month ago, were positive.
INOpulse is a drug-device combination system that delivers pulsed doses of nitric oxide.
https://seekingalpha.com/news/3550140-bellerophon-sets-late-stage-study-of-inopulse-for-ph-shares-up-12
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.